Bristol Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

 Transaction Brings RayzeBio’s Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb’s Leading Oncology Franchise

Lead Program, RYZ101, in Phase 3 Development for Treatment of Gastroenteropancreatic Neuroendocrine Tumors and Early-stage Development for Treatment of Small Cell Lung Cancer and Potentially Other Tumor Types

Gains Robust IND Engine and State of the Art Radiopharmaceutical Manufacturing Capabilities

https://www.globenewswire.com/news-release/2023/12/26/2801050/0/en/Bristol-Myers-Squibb-Adds-Premier-Radiopharmaceutical-Platform-with-Acquisition-of-RayzeBio.html